[ORGANIZATION]
Regeneron
Featured in 10 tracked stories · first seen
Situations
Expanding therapeutic uses and regulatory concerns for GLP-1
36 clusters · 160 sources · last updated
Latest: Semaglutide treatments face high discontinuation rates
Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow
Clinical efficacy of upadacitinib in dermatological studies
2 clusters · 6 sources · last updated
Latest: Upadacitinib shows promise in treating severe alopecia areata
Clinical research has highlighted the efficacy of the medication upadacitinib across different dermatological conditions. In studies regarding atopic dermatitis, data presented at the 2026 Fall Clinical Dermatology Conf
Also covered in
-
Regeneron extends $270 million US Ebola treatment deal to 2031
[HEALTH] · 3 sources ·
-
Cemdisiran shows potential in Phase 3 myasthenia gravis trial
[HEALTH] · 2 sources ·
-
Clinical trials play a vital role in medical research and drug safety
[HEALTH] · 2 sources ·
-
Dupilumab shows efficacy in pediatric dermatitis and urticaria
[HEALTH] · 2 sources ·
-
Sanofi Raises 2026 Revenue Target After Strong Mid‑Year Results
[BUSINESS] · 5 sources ·